Nifty
:
15699.25
Sensex
:
52727.98
142.60 (0.92%)
462.26 (0.88%)
Nifty
Sensex
:
:
15699.25
52727.98
142.60 (0.92%)
462.26 (0.88%)

Glaxosmithkline Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Domestic

Rating :
66/99

BSE: 500660 | NSE: GLAXO

NSE BSE
1499.80
24-Jun-2022
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 1500.00
  • 1517.95
  • 1497.85
  • 1499.75
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  23915
  •  359.12
  •  1918.75
  •  1450.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 25,406.67
  • 15.02
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 22,927.56
  • 6.00%
  • 9.56

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 75.00%
  • 0.53%
  • 10.41%
  • FII
  • DII
  • Others
  • 2.18%
  • 9.22%
  • 2.66%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 1.92
  • 0.75

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 10.66
  • 2.97

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 1.24
  • -7.01

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 60.81
  • 62.07
  • 61.00

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 13.88
  • 13.63
  • 15.45

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 35.45
  • 34.63
  • 31.49

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Sep 21
Sep 20
Var%
Jun 21
Jun 20
Var%
Net Sales
809.63
744.43
8.76%
815.92
791.87
3.04%
1,009.87
879.32
14.85%
789.99
648.59
21.80%
Expenses
634.41
587.75
7.94%
618.11
611.21
1.13%
733.35
674.46
8.73%
638.32
534.52
19.42%
EBITDA
175.22
156.68
11.83%
197.81
180.66
9.49%
276.52
204.86
34.98%
151.67
114.07
32.96%
EBIDTM
21.64%
21.05%
24.24%
22.81%
27.38%
23.30%
19.20%
17.59%
Other Income
18.76
29.60
-36.62%
10.32
14.02
-26.39%
14.97
9.04
65.60%
31.73
57.92
-45.22%
Interest
0.28
0.63
-55.56%
0.58
0.94
-38.30%
0.35
0.88
-60.23%
0.79
1.08
-26.85%
Depreciation
15.35
17.68
-13.18%
17.87
17.54
1.88%
17.60
21.96
-19.85%
17.71
21.77
-18.65%
PBT
207.85
48.97
324.44%
171.76
186.73
-8.02%
273.54
126.93
115.50%
164.90
149.14
10.57%
Tax
262.51
45.32
479.24%
33.48
47.48
-29.49%
69.30
50.46
37.34%
43.82
38.31
14.38%
PAT
-54.66
3.65
-
138.28
139.25
-0.70%
204.24
76.47
167.09%
121.08
110.83
9.25%
PATM
-6.75%
0.49%
16.95%
17.59%
20.22%
8.70%
15.33%
17.09%
EPS
71.96
0.85
8,365.88%
8.87
9.24
-4.00%
12.06
4.51
167.41%
7.15
6.54
9.33%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Dec 13
Dec 12
Dec 11
Net Sales
3,425.41
3,198.86
3,224.38
3,128.12
2,871.45
2,908.47
2,837.91
3,362.91
2,607.70
2,692.06
2,455.38
Net Sales Growth
11.79%
-0.79%
3.08%
8.94%
-1.27%
2.49%
-15.61%
28.96%
-3.13%
9.64%
 
Cost Of Goods Sold
1,384.75
1,312.71
1,307.87
1,358.03
1,241.31
1,397.75
1,324.90
1,327.66
1,171.68
1,100.57
923.50
Gross Profit
2,040.66
1,886.15
1,916.51
1,770.09
1,630.14
1,510.72
1,513.02
2,035.25
1,436.02
1,591.49
1,531.87
GP Margin
59.57%
58.96%
59.44%
56.59%
56.77%
51.94%
53.31%
60.52%
55.07%
59.12%
62.39%
Total Expenditure
2,624.19
2,503.53
2,567.13
2,527.32
2,365.66
2,489.49
2,359.64
2,788.33
2,124.49
1,915.22
1,693.90
Power & Fuel Cost
-
26.08
33.36
27.94
26.44
27.82
25.97
31.17
23.85
22.50
26.70
% Of Sales
-
0.82%
1.03%
0.89%
0.92%
0.96%
0.92%
0.93%
0.91%
0.84%
1.09%
Employee Cost
-
614.69
628.55
537.20
523.40
483.01
443.37
493.02
362.05
295.52
278.36
% Of Sales
-
19.22%
19.49%
17.17%
18.23%
16.61%
15.62%
14.66%
13.88%
10.98%
11.34%
Manufacturing Exp.
-
106.55
107.89
115.55
110.55
108.26
118.09
367.24
127.78
113.62
111.44
% Of Sales
-
3.33%
3.35%
3.69%
3.85%
3.72%
4.16%
10.92%
4.90%
4.22%
4.54%
General & Admin Exp.
-
118.87
164.51
178.60
204.45
195.08
154.85
178.21
135.34
126.10
108.51
% Of Sales
-
3.72%
5.10%
5.71%
7.12%
6.71%
5.46%
5.30%
5.19%
4.68%
4.42%
Selling & Distn. Exp.
-
190.92
212.36
202.81
154.38
178.91
164.47
222.31
186.23
160.74
157.60
% Of Sales
-
5.97%
6.59%
6.48%
5.38%
6.15%
5.80%
6.61%
7.14%
5.97%
6.42%
Miscellaneous Exp.
-
133.71
112.58
107.20
105.12
98.67
127.99
168.72
117.55
96.17
157.60
% Of Sales
-
4.18%
3.49%
3.43%
3.66%
3.39%
4.51%
5.02%
4.51%
3.57%
3.58%
EBITDA
801.22
695.33
657.25
600.80
505.79
418.98
478.27
574.58
483.21
776.84
761.48
EBITDA Margin
23.39%
21.74%
20.38%
19.21%
17.61%
14.41%
16.85%
17.09%
18.53%
28.86%
31.01%
Other Income
75.78
110.58
79.01
102.32
54.54
73.07
123.18
258.80
222.30
223.90
186.59
Interest
2.00
3.53
6.34
0.55
0.19
0.25
0.42
0.47
0.33
0.33
0.33
Depreciation
68.53
79.28
82.68
48.59
37.99
26.35
24.95
25.35
19.88
17.84
20.41
PBT
818.05
723.10
647.25
653.97
522.17
465.46
576.08
807.56
685.30
982.58
927.33
Tax
409.11
192.35
212.55
237.28
189.24
174.37
202.25
279.27
229.78
272.48
176.20
Tax Rate
50.01%
34.94%
69.52%
34.76%
35.05%
34.11%
34.97%
36.96%
32.30%
32.66%
29.13%
PAT
408.94
358.15
93.20
445.39
350.73
336.81
376.14
476.41
481.67
561.88
428.59
PAT before Minority Interest
408.94
358.15
93.20
445.39
350.73
336.81
376.14
476.41
481.67
561.88
428.59
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
11.94%
11.20%
2.89%
14.24%
12.21%
11.58%
13.25%
14.17%
18.47%
20.87%
17.46%
PAT Growth
23.85%
284.28%
-79.07%
26.99%
4.13%
-10.46%
-21.05%
-1.09%
-14.28%
31.10%
 
EPS
24.14
21.14
5.50
26.29
20.70
19.88
22.20
28.12
28.43
33.17
25.30

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Dec 13
Dec 12
Dec 11
Shareholder's Funds
1,499.08
1,820.60
2,139.83
2,057.33
2,006.86
2,183.25
1,828.98
1,989.73
2,006.83
1,935.70
Share Capital
169.41
169.41
169.41
84.70
84.70
84.70
84.70
84.70
84.70
84.70
Total Reserves
1,329.67
1,651.20
1,970.42
1,972.63
1,922.15
2,098.55
1,744.28
1,905.03
1,922.13
1,851.00
Non-Current Liabilities
178.68
180.19
2,860.37
2,632.47
3,699.70
3,498.32
197.04
158.59
158.45
172.78
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
0.00
0.02
0.18
0.58
0.99
1.60
2.63
3.61
4.14
4.59
Long Term Provisions
259.50
261.74
2,920.20
2,733.36
3,786.83
3,592.19
272.21
242.29
236.05
224.81
Current Liabilities
1,332.47
1,021.95
2,804.07
2,948.98
881.09
783.63
1,106.55
888.91
836.40
859.59
Trade Payables
464.47
357.06
405.81
505.86
278.93
327.74
308.04
285.63
237.37
200.58
Other Current Liabilities
450.11
222.85
802.71
842.35
390.47
202.82
130.09
84.13
86.82
67.25
Short Term Borrowings
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Short Term Provisions
417.90
442.04
1,595.54
1,600.77
211.69
253.08
668.42
519.15
512.21
591.77
Total Liabilities
3,010.23
3,022.74
7,804.27
7,638.78
6,587.65
6,465.20
3,132.57
3,037.23
3,001.68
2,968.07
Net Block
384.27
756.59
429.99
322.81
252.71
204.04
123.08
100.09
89.42
99.15
Gross Block
614.71
1,452.35
559.05
405.89
299.09
228.36
363.34
343.22
316.18
315.80
Accumulated Depreciation
230.44
695.76
129.06
83.08
46.38
24.32
240.26
243.13
226.76
216.65
Non Current Assets
807.58
1,247.87
4,445.06
4,103.26
4,752.54
4,087.05
545.58
413.30
355.01
363.01
Capital Work in Progress
13.21
120.12
1,002.64
922.90
605.46
267.67
115.22
61.86
43.79
16.19
Non Current Investment
1.35
1.49
1.69
1.84
5.40
6.04
0.06
0.06
10.06
54.98
Long Term Loans & Adv.
401.71
362.49
3,002.88
2,850.97
3,882.49
3,609.24
296.09
237.73
194.55
157.01
Other Non Current Assets
7.03
7.17
7.84
4.75
6.47
0.06
11.13
13.55
17.19
35.68
Current Assets
2,202.65
1,774.88
3,359.21
3,535.52
1,835.10
2,378.15
2,586.98
2,623.94
2,646.67
2,605.06
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
10.00
44.91
57.21
Inventories
546.70
483.03
486.49
500.18
425.80
525.87
375.58
346.97
285.15
333.44
Sundry Debtors
215.60
99.80
120.49
146.96
170.80
126.56
100.32
96.39
115.90
85.31
Cash & Bank
1,157.98
1,083.20
1,171.35
1,296.41
899.61
1,391.90
1,910.61
2,041.58
2,066.77
2,014.36
Other Current Assets
282.38
48.58
112.30
78.72
338.90
333.82
200.47
128.99
133.94
114.74
Short Term Loans & Adv.
57.64
60.27
1,468.58
1,513.25
232.20
310.58
112.04
71.19
58.18
50.12
Net Current Assets
870.18
752.93
555.14
586.54
954.01
1,594.52
1,480.43
1,735.03
1,810.27
1,745.46
Total Assets
3,010.23
3,022.75
7,804.27
7,638.78
6,587.64
6,465.20
3,132.56
3,037.24
3,001.68
2,968.07

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Dec 13
Dec 12
Dec 11
Cash From Operating Activity
577.93
490.50
409.49
472.80
234.37
138.90
337.64
281.31
313.59
335.37
PBT
723.10
647.25
653.97
522.17
465.46
576.08
807.56
685.30
982.58
927.33
Adjustment
-25.64
13.17
-31.36
-12.17
-46.47
-96.01
-173.66
-156.37
-159.63
-139.38
Changes in Working Capital
45.76
44.07
-4.19
164.56
-26.69
-124.41
-36.90
11.45
56.35
-73.09
Cash after chg. in Working capital
743.21
704.49
618.41
674.55
392.29
355.67
597.00
540.37
879.30
714.86
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-146.95
-179.72
-194.24
-202.01
-160.59
-205.95
-252.43
-244.09
-318.38
-316.53
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
-18.34
-34.26
-14.69
0.25
2.67
-10.82
-6.93
0.00
0.00
0.00
Cash From Investing Activity
418.59
-56.84
-153.45
-104.19
300.64
499.02
180.01
188.98
-109.65
358.03
Net Fixed Assets
958.61
-10.78
-232.90
-424.24
-408.52
-61.62
-73.47
-45.11
-27.98
39.27
Net Investments
0.15
0.20
23.26
3.56
0.64
-5.96
10.00
44.92
57.21
0.55
Others
-540.17
-46.26
56.19
316.49
708.52
566.60
243.48
189.17
-138.88
318.21
Cash from Financing Activity
-696.14
-427.62
-358.36
-306.63
-510.76
-638.33
-496.99
-494.14
-440.63
-394.81
Net Cash Inflow / Outflow
300.38
6.03
-102.33
61.97
24.24
-0.42
20.66
-23.85
-236.69
298.59
Opening Cash & Equivalents
104.81
98.78
201.10
139.13
114.89
115.30
94.93
137.67
374.36
75.77
Closing Cash & Equivalent
405.19
104.81
98.78
201.10
139.13
114.89
115.59
113.82
137.67
374.36

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Dec 13
Dec 12
Dec 11
Book Value (Rs.)
88.49
107.47
126.31
121.44
118.46
128.88
107.96
117.45
118.46
114.26
ROA
11.87%
1.72%
5.77%
4.93%
5.16%
7.84%
15.44%
15.95%
18.82%
10.65%
ROE
21.58%
4.71%
21.22%
17.26%
16.08%
18.75%
24.95%
24.10%
28.50%
22.05%
ROCE
33.38%
15.76%
32.54%
26.56%
24.39%
28.82%
39.53%
35.54%
42.24%
31.05%
Fixed Asset Turnover
3.10
3.21
6.48
8.21
11.38
9.59
9.82
8.13
8.74
7.40
Receivable days
17.99
12.47
15.60
20.03
18.09
14.59
10.35
14.45
13.29
9.62
Inventory Days
58.75
54.88
57.56
58.36
57.89
57.97
38.01
43.02
40.86
45.01
Payable days
114.21
57.89
73.24
66.07
51.56
53.81
43.72
49.18
47.40
62.14
Cash Conversion Cycle
-37.47
9.45
-0.07
12.32
24.42
18.75
4.64
8.28
6.75
-7.51
Total Debt/Equity
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Interest Cover
156.89
49.26
1232.59
2856.45
2045.74
1373.88
1612.26
2146.51
2497.59
1848.25

Annual Reports:

FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011

News Update:


  • Glaxosmithkline Pharmaceuticals reports many fold jump in Q4 consolidated net profit
    17th May 2022, 14:08 PM

    Total consolidated income of the company increased by 7.02% at Rs 828.39 crore for Q4FY22

    Read More
  • Glaxosmithkline Phar - Quarterly Results
    16th May 2022, 16:35 PM

    Read More
  • GlaxoSmithKline Pharmaceuticals launches Trelegy Ellipta for COPD patients
    26th Apr 2022, 16:29 PM

    Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is the first once daily single-inhaler triple therapy (SITT) in India for COPD patients

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.